tiprankstipranks
Apollomics announces results from Phase 3 bridging trial of uproleselan
PremiumThe FlyApollomics announces results from Phase 3 bridging trial of uproleselan
6M ago
Apollomics Inc trading resumes
Premium
The Fly
Apollomics Inc trading resumes
6M ago
Apollomics Inc trading halted, volatility trading pause
Premium
The Fly
Apollomics Inc trading halted, volatility trading pause
6M ago
Apollomics Inc trading halted, news pending
PremiumThe FlyApollomics Inc trading halted, news pending
7M ago
Apollomics announces approval, date for 1-for-100 reverse share split
Premium
The Fly
Apollomics announces approval, date for 1-for-100 reverse share split
7M ago
Apollomics presents Vebreltinib  data in patients with NSCLC
Premium
The Fly
Apollomics presents Vebreltinib data in patients with NSCLC
9M ago
Apollomics announces approval of vebreltinib in China
PremiumThe FlyApollomics announces approval of vebreltinib in China
1y ago
Apollomics presents vebreltinib data at AACR meeting
Premium
The Fly
Apollomics presents vebreltinib data at AACR meeting
1y ago
Apollomics price target lowered to $5 from $17 at H.C. Wainwright
Premium
The Fly
Apollomics price target lowered to $5 from $17 at H.C. Wainwright
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100